NEW YORK (360Dx) – Exosome Diagnostics said that the national Medicare reimbursement price for its ExoDx Prostate IntelliScore (EPI) test has been set by the US Centers for Medicare and Medicaid Services at $760. The test has been added to the 2018 Clinical Laboratory Fee schedule, effective Jan. 1, 2018, the firm added.

EPI is a urine-based test that looks for three exosomal RNA biomarkers expressed in men with high-grade prostate cancer to help in the biopsy decision-making process.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.